Novamind Inc.

CSE: NM

Company Logo

Company Overview

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.

Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.

Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

$0.00

Diluted EPS (ttm)

Management Team

Mr. Yaron Conforti
Co-Founder, CEO & Director

Mr. Yisroel Weinreb
Co-Founder & Director

Mr. Jesse Armin Kaplan C.F.A.
Co-Founder & Director

Mr. Jing Peng C.A., CPA
CFO & Corp. Sec.

Mr. Pierre Bou-Mansour P.Eng.
Chief Operating Officer

Dr. Paul Thielking M.D.
Chief Scientific Officer & Principal Investigator and Member of Scientific Advisory Board

Ms. Samantha DeLenardo
VP of Communications

Mr. Prakash Gowd B.Sc., B.Sc. (Pharm), MBA
Sr. VP of Corp. Devel.

Mr. Coby Gerstner
Director of Branding & Marketing

Dr. Reid J. Robison
Chief Medical Officer & Director

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
9,074 (0%)

Insider Ownership
32%